• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Analysis of Previous Infection, Vaccinations, and Anti-SARS-CoV-2 Antibody Titers and Protection Against Infection With the SARS-CoV-2 Omicron BA.5 Variant.

作者信息

Yamamoto Shohei, Mizoue Tetsuya, Ohmagari Norio

机构信息

Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

出版信息

JAMA Netw Open. 2023 Mar 1;6(3):e233370. doi: 10.1001/jamanetworkopen.2023.3370.

DOI:10.1001/jamanetworkopen.2023.3370
PMID:36929403
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10020878/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fdc/10020878/9587dbba47ea/jamanetwopen-e233370-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fdc/10020878/9587dbba47ea/jamanetwopen-e233370-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fdc/10020878/9587dbba47ea/jamanetwopen-e233370-g001.jpg

相似文献

1
Analysis of Previous Infection, Vaccinations, and Anti-SARS-CoV-2 Antibody Titers and Protection Against Infection With the SARS-CoV-2 Omicron BA.5 Variant.既往感染、疫苗接种及抗SARS-CoV-2抗体滴度分析与针对SARS-CoV-2奥密克戎BA.5变体感染的防护
JAMA Netw Open. 2023 Mar 1;6(3):e233370. doi: 10.1001/jamanetworkopen.2023.3370.
2
SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.养老院居民接种二价 COVID-19 疫苗后对原始 SARS-CoV-2 株和奥密克戎 BA.1 和 BA.4/BA.5 变异株的 SARS-CoV-2 抗体反应 - 俄亥俄州和罗得岛，2022 年 9 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2023 Jan 27;72(4):100-106. doi: 10.15585/mmwr.mm7204a4.
3
A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.一种异源挑战可挽救 SARS-CoV-2 奥密克戎 BA.1 变异株在叙利亚仓鼠模型中的减毒免疫原性。
J Virol. 2023 Feb 28;97(2):e0168422. doi: 10.1128/jvi.01684-22. Epub 2023 Jan 18.
4
Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.第三剂 mRNA 疫苗接种后对 SARS-CoV-2 奥密克戎 BA.1、BA.2 和 BA.3 的抗体亲和力和跨变体中和作用。
Nat Commun. 2022 Aug 8;13(1):4617. doi: 10.1038/s41467-022-32298-w.
5
SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.Omicron BA.1 变异株突破感染同源第三剂 Comirnaty® COVID-19 疫苗后的养老院居民：寻找保护相关因素。
J Med Virol. 2022 Sep;94(9):4216-4223. doi: 10.1002/jmv.27867. Epub 2022 May 25.
6
Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron.奥密克戎突破感染时的抗刺突蛋白抗体滴度。
J Infect Chemother. 2022 Jul;28(7):1015-1017. doi: 10.1016/j.jiac.2022.03.021. Epub 2022 Apr 1.
7
Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.感染或接种疫苗后针对 SARS-CoV-2 奥密克戎变异株的抗体亲合力和中和反应。
J Immunol Res. 2022 Aug 31;2022:4813199. doi: 10.1155/2022/4813199. eCollection 2022.
8
Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.估计 BNT162b2 疫苗对美国 5 至 11 岁儿童感染德尔塔和奥密克戎变异株的有效性。
JAMA Netw Open. 2022 Dec 1;5(12):e2246915. doi: 10.1001/jamanetworkopen.2022.46915.
9
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.疫苗对 Alpha、Delta 或奥密克戎变异株引起的 SARS-CoV-2 感染或 COVID-19 住院的有效性：一项全国性丹麦队列研究。
PLoS Med. 2022 Sep 1;19(9):e1003992. doi: 10.1371/journal.pmed.1003992. eCollection 2022 Sep.
10
Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.中国衢州 2022 年 3 月至 5 月两次疫情期间 COVID-19 疫苗对 SARS-CoV-2 奥密克戎变异株的有效性。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2163813. doi: 10.1080/21645515.2022.2163813. Epub 2023 Jan 27.

引用本文的文献

1
Symptomatology and IgG Levels before and after SARS-CoV-2 Omicron Breakthrough Infections in Vaccinated Individuals.接种疫苗个体中SARS-CoV-2奥密克戎突破性感染前后的症状学和IgG水平
Vaccines (Basel). 2024 Oct 8;12(10):1149. doi: 10.3390/vaccines12101149.
2
Correlates of Nucleocapsid Antibodies and a Combination of Spike and Nucleocapsid Antibodies Against Protection of SARS-CoV-2 Infection During the Omicron XBB.1.16/EG.5-Predominant Wave.在奥密克戎XBB.1.16/EG.5为主的疫情波期间，核衣壳抗体以及刺突蛋白和核衣壳抗体组合与预防新冠病毒感染的相关性
Open Forum Infect Dis. 2024 Aug 28;11(9):ofae455. doi: 10.1093/ofid/ofae455. eCollection 2024 Sep.
3

本文引用的文献

1
Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.奥密克戎 BA.2 突破感染增强了对 BA.2.12.1 和 BA.4/BA.5 的交叉中和作用。
Sci Immunol. 2022 Nov 25;7(77):eade2283. doi: 10.1126/sciimmunol.ade2283. Epub 2022 Nov 18.
2
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.严重急性呼吸综合征冠状病毒2型奥密克戎亚变体BA.2.12.1、BA.4和BA.5的中和逃逸
N Engl J Med. 2022 Jul 7;387(1):86-88. doi: 10.1056/NEJMc2206576. Epub 2022 Jun 22.
3
Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study.
Effectiveness and duration of additional immune defense provided by SARS-CoV-2 infection before and after receiving the mRNA COVID-19 vaccine BNT162b2.
接种mRNA新冠疫苗BNT162b2前后，SARS-CoV-2感染提供的额外免疫防御的有效性和持续时间。
Vaccine X. 2024 Jun 26;19:100518. doi: 10.1016/j.jvacx.2024.100518. eCollection 2024 Aug.
4
Rapid Wane and Recovery of XBB Sublineage Neutralization After Sequential Omicron-based Vaccination in Solid Organ Transplant Recipients.序贯接种基于奥密克戎的疫苗后，实体器官移植受者中 XBB 亚系中和作用迅速减弱和恢复。
Clin Infect Dis. 2024 Sep 26;79(3):652-655. doi: 10.1093/cid/ciae279.
5
Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination.奥瑞珠单抗治疗的多发性硬化症患者在 COVID-19 疫苗接种后长达 2 年对 SARS-CoV2 免疫的纵向研究。
Ann Clin Transl Neurol. 2024 Jul;11(7):1750-1764. doi: 10.1002/acn3.52081. Epub 2024 May 7.
6
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study.免疫抑制治疗患者中疫苗和混合免疫后 COVID-19 的发生率和结局：前瞻性队列研究中识别免疫后抗 RBD 抗体的保护性水平。
RMD Open. 2024 Apr 9;10(2):e003545. doi: 10.1136/rmdopen-2023-003545.
7
Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection.免疫和行为因素与接种疫苗后预防有症状的 SARS-CoV-2 感染的相关性。
Front Immunol. 2024 Mar 19;15:1287504. doi: 10.3389/fimmu.2024.1287504. eCollection 2024.
8
Longitudinal antibody dynamics after COVID-19 vaccine boosters based on prior infection status and booster doses.基于既往感染状况和加强针剂，COVID-19 疫苗加强针后的抗体纵向动力学。
Sci Rep. 2024 Feb 25;14(1):4564. doi: 10.1038/s41598-024-55245-9.
9
Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants.母亲接种 COVID-19 疫苗与预防婴儿出现症状感染。
Pediatrics. 2024 Mar 1;153(3). doi: 10.1542/peds.2023-064252.
10
Protection of COVID-19 Vaccination Against Hospitalization During the Era of Omicron BA.4 and BA.5 Predominance: A Nationwide Case-Control Study Based on the French National Health Data System.奥密克戎BA.4和BA.5占主导时期新冠疫苗接种对住院的保护作用：基于法国国家卫生数据系统的全国性病例对照研究
Open Forum Infect Dis. 2023 Sep 8;10(10):ofad460. doi: 10.1093/ofid/ofad460. eCollection 2023 Oct.
东京一家转诊医院医护人员中2019冠状病毒病（COVID-19）突破性感染及接种疫苗后的中和抗体：一项病例对照匹配研究
Clin Infect Dis. 2022 Aug 24;75(1):e683-e691. doi: 10.1093/cid/ciab1048.